Aclaris Therapeutics (ACRS) CBO logs RSU vesting and tax share withholding

Rhea-AI Filing Summary

Aclaris Therapeutics, Inc.'s Chief Business Officer reported multiple equity compensation events on February 1, 2026. Several restricted stock unit (RSU) awards were exercised (transaction code M), delivering 11,250, 7,500, and 14,750 shares of common stock in separate transactions.

The filing also reports a transaction coded F, where 10,686 shares were withheld at $3.51 per share to cover tax obligations tied to RSU vesting. The RSU grants vest in four equal annual installments starting on February 1 of 2022, 2023, and 2024, subject to continued service. This amendment corrects a prior filing that mistakenly referenced a February 1, 2025 transaction due to a filing platform error.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Loerop James

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/01/2026		M		11,250	A	(1)	165,758	D
Common Stock	02/01/2026		M		7,500	A	(1)	173,258	D
Common Stock	02/01/2026		M		14,750	A	(1)	188,008	D
Common Stock	02/01/2026		F(2)		10,686	D	$3.51	177,322	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/01/2026		M			11,250	(3)	(3)	Common Stock	11,250	$0	0	D
Resticted Stock Units	(1)	02/01/2026		M			7,500	(4)	(4)	Common Stock	7,500	$0	7,500	D
Restricted Stock Units	(1)	02/01/2026		M			14,750	(5)	(5)	Common Stock	14,750	$0	29,500	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

2. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

3. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

4. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

5. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Remarks:

This filing amends and restates the Form 4 filed on February 3, 2026 that erroneously reported a February 1, 2025 transaction due to an error with the filing platform.

	/s/ Matthew Rothman, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Aclaris Therapeutics (ACRS) report in this Form 4/A?

The filing reports the Chief Business Officer’s restricted stock units converting into common stock and related tax share withholding on February 1, 2026. Multiple RSU tranches vested and were settled in shares, with some shares withheld to satisfy tax obligations.

Who is the reporting person in this Aclaris Therapeutics (ACRS) Form 4/A?

The reporting person is Aclaris Therapeutics’ Chief Business Officer, identified as an officer of the company. The individual reports beneficial ownership of common stock directly, reflecting changes from RSU vesting and tax share withholding on February 1, 2026.

What RSU-related stock transactions occurred on February 1, 2026 for ACRS?

On February 1, 2026, three RSU awards were exercised, delivering 11,250, 7,500, and 14,750 Aclaris common shares in separate transactions. These events are coded M, showing conversions from RSUs into common stock at a stated exercise price of $0 for the derivative securities.

Why were 10,686 Aclaris (ACRS) shares withheld in this insider filing?

The filing shows 10,686 shares withheld at $3.51 per share, coded F, to satisfy the reporting person’s tax withholding obligations. This withholding is tied to the vesting and settlement of RSUs and reduces the net shares delivered to the officer.

What vesting schedules apply to the Aclaris (ACRS) RSUs in this Form 4/A?

The RSUs vest in four equal annual installments on the first through fourth anniversaries of February 1, 2022, 2023, and 2024. Vesting is subject to the officer’s continuous service under the company’s plan as of each applicable anniversary date.

Why was the original Aclaris (ACRS) Form 4 amended and restated?

The amendment states the prior Form 4, filed February 3, 2026, erroneously reported a February 1, 2025 transaction. The error arose from the filing platform, so this Form 4/A corrects the transaction date to February 1, 2026 and restates the details.